DMSO 70/30 3 oz. Roll-on w/Aloe Vera 3 Pack 99.995% Low odor Pharma Grade
Price : 34.99
Ends on : N/A
View on eBay
Introducing our DMSO 70/30 3 oz. Roll-on with Aloe Vera 3 Pack! Made with 99.995% low odor Pharma Grade DMSO, this powerful roll-on is perfect for targeting sore muscles and joints. The added Aloe Vera helps soothe and moisturize the skin, making it gentle enough for daily use.
Whether you’re an athlete looking for relief after a tough workout or simply dealing with everyday aches and pains, this DMSO roll-on is a must-have in your medicine cabinet. Simply roll on the affected area and feel the cooling, soothing sensation take effect.
Don’t let discomfort hold you back – try our DMSO 70/30 3 oz. Roll-on with Aloe Vera 3 Pack today and experience the difference for yourself!
#DMSO #Rollon #wAloe #Vera #Pack #odor #Pharma #Grade,ages 3+
DMSO 70/30 3 oz. Roll-on w/Aloe Vera 10 Pack 99.995% Low odor Pharma Grade
Price : 99.99
Ends on : N/A
View on eBay
Looking for a convenient and effective way to use DMSO? Look no further than our DMSO 70/30 3 oz. Roll-on w/Aloe Vera 10 Pack! This product is made with 99.995% low odor Pharma Grade DMSO, ensuring top quality and purity.
The roll-on design makes application a breeze, and the added Aloe Vera helps to soothe and hydrate the skin. Each pack contains 10 roll-ons, so you’ll have plenty on hand for all your needs.
Whether you’re looking for pain relief, inflammation reduction, or simply want to improve the absorption of other topical products, our DMSO roll-ons are the perfect solution. Order yours today and experience the benefits for yourself!
#DMSO #Rollon #wAloe #Vera #Pack #odor #Pharma #Grade,ages 3+
Members of the family who own OxyContin maker Purdue Pharma agreed to pay up to $7.4bn in a new settlement to lawsuits over the toll of the powerful prescription painkiller, the New York Aattorney Ggeneral, Letitia James, announced Thursday.
The deal, agreed to by Purdue Pharma, the Sackler family members who own the company and lawyers representing state and local governments and thousands of victims of the opioid crisis, represents an increase of more than $1bn over a previous settlement deal that was rejected last year by the US supreme court.
It’s among the largest settlements reached over the past several years in a series of lawsuits by local, state, Native American tribal governments and others seeking to hold companies responsible for a deadly epidemic. Aside from the Purdue deal, others worth about $50bn have been announced – and most of the money is required to be used to stem the crisis.
The deal still needs court approval, and some of the details are yet to be ironed out.
Under the new proposal, members of the Sackler family who own Purdue would contribute up to $7.4bn over 15 years and give up ownership of Purdue, which would become a new entity with its board appointed by states and others who sued the company. A portion of the money is also to go to victims of the opioid crisis or their survivors.
The family’s contribution will be higher than the $6bn agreed to under the previous version. The supreme court blocked the agreement last year because it protected members of the wealthy family from civil lawsuits over OxyContin – even though the family members themselves were not in bankruptcy. The new agreement protects family members from lawsuits only from entities that agree to the settlement.
There’s been mediation seeking a new deal since the court’s ruling was delivered. If one is not reached, it could open the floodgates to lawsuits against Sackler family members.
The new settlement could bring to a close a chapter in a long legal saga over the toll of an opioid crisis that some experts assert began after the blockbuster painkiller OxyContin hit the market in 1996. Since then, opioids have been linked to hundreds of thousands of deaths in the US. The deadliest stretch has been since 2020, when illicit fentanyl has been found as a factor in more than 70,000 deaths annually.
Members of the Sackler family been cast as villains and have seen their name removed from art galleries and universities around the world because of their role in the privately held company. They have continued to deny claims of any wrongdoing.
Collectively, family members have been estimated to be worth billions more than they’d contribute in the settlement, but much of the wealth is in offshore accounts and might be impossible to access through lawsuits.
Purdue sought bankruptcy protection in 2019 as it faced thousands of lawsuits over the opioid crisis. Among the claims are that the company targeted doctors with a message that the addiction risk to the powerful painkillers was low.
In an October 2024 filing, one branch of the family pledged to defend itself in any cases that are allowed to move ahead, saying that the legal theory at the heart of the lawsuits – that Purdue and Sackler family members created a “public nuisance” – “is utterly devoid of merits”.
Purdue Pharma and the Sackler family have reached a new $7.4 billion settlement over their role in the opioids crisis. The settlement, which was announced on Thursday, comes after years of legal battles and public outrage over the company’s aggressive marketing of OxyContin and other opioid drugs.
Under the terms of the settlement, Purdue Pharma will be dissolved and its assets will be used to create a new public benefit company that will be dedicated to addressing the opioid crisis. The Sackler family, who owns Purdue Pharma, will also contribute $4.5 billion to the settlement from their personal fortune.
This settlement marks a significant step towards holding Purdue Pharma and the Sacklers accountable for their role in fueling the opioids crisis, which has claimed the lives of hundreds of thousands of Americans. However, many advocates and lawmakers argue that the settlement is not enough to fully address the harm caused by the company’s actions.
The opioids crisis continues to be a major public health issue in the United States, with millions of Americans struggling with addiction and overdose deaths on the rise. It is clear that more needs to be done to prevent future crises and support those who have been affected by the devastating impact of opioid addiction.
Tags:
Purdue Pharma, Sacklers, $7.4bn settlement, opioids crisis, pharmaceutical company, opioid epidemic, opioid addiction, drug crisis, legal settlement, drug manufacturers, opioid lawsuit, drug abuse epidemic
The company and the once-prominent family behind the drug OxyContin agreed Thursday to increase their financial contribution to resolve mass opioid litigation.
The Sacklers and Purdue Pharma boosted their settlement contribution to $7.4 billion after the U.S. Supreme Court overturned a prior settlement in June 2024. If approved, the new plan would end the costliest corporate bankruptcy resulting from the U.S. opioid crisis.
Purdue, under the leadership of the Sackler families, invented, manufactured and aggressively marketed opioid products for decades, according to the lawsuits. States and cities across the country said it fueled waves of addiction and overdose deaths.
The pharmaceutical company introduced OxyContin, a brand name of oxycodone, in the 1990s and filed for chapter 11 bankruptcy in 2019 after the company was sued thousands of times.
Under the settlement terms, the Sacklers’ control of Purdue Pharma ends. The $7.4 billion will go directly to communities across the U.S. — including states, counties, cities and territories — over the next 15 years to support opioid addiction treatment, prevention, and recovery programs.
The Sacklers will also no longer have liability protection from future lawsuits as they previously demanded.
Bottles of prescription painkiller OxyContin pills, made by Purdue Pharma LP sit on a counter at a local pharmacy in Provo, Utah, April 25, 2017.
George Frey/Reuters, FILE
“Families throughout New York and across the nation are suffering from the immense pain and loss wrought by the opioid crisis,” said New York Attorney General Letitia James, whose office helped negotiate the settlement agreement.
“The Sackler family relentlessly pursued profit at the expense of vulnerable patients, and played a critical role in starting and fueling in the opioid epidemic,” she continued. “While no amount of money will ever fully repair the damage they caused, this massive influx of funds will bring resources to communities in need so that we can heal.”
Purdue Pharma planned to exit bankruptcy last year under terms that gave the Sacklers a full release from all civil opioid claims even though they themselves were not declaring bankruptcy. In return, the Sacklers agreed to pay $6 billion.
The Supreme Court rejected the attempt by the Sacklers to use Purdue Pharma’s bankruptcy to shield themselves from liability.
Under the new terms, a significant amount of the settlement funds will be distributed in the first three years, with the Sacklers paying $1.5 billion and Purdue paying nearly $900 million in the first payment, followed by $500 million after one year, an additional $500 million after two years, and $400 million after three years.
A board of trustees selected by participating states in consultation with the other creditors will determine the future of the company. Purdue will continue to be overseen by a monitor and will be prevented from lobbying or marketing opioids.
“This story is about a family of cruel billionaires who believed they were above the law, pursued by states who never backed down,” Connecticut Attorney General William Tong said Thursday. “Today, we are forcing Purdue Pharma and the Sackler family to pay $7.4 billion for their role in igniting one of the most devastating public health crises in American history.”
Purdue Pharma said in a statement to ABC News, “We are extremely pleased that a new agreement has been reached that will deliver billions of dollars to compensate victims, abate the opioid crisis, and deliver treatment and overdose rescue medicines that will save lives. We have worked intensely with our creditors for months in mediation, and we are now focused on finalizing the details of a new Plan of Reorganization, which we look forward to presenting to the bankruptcy court.”
In a major development in the ongoing legal battle over the opioid crisis, Purdue Pharma and the Sackler families have agreed to increase their contribution to the settlement to $7.4 billion. This substantial increase comes as a response to mounting pressure from state and local governments, as well as advocacy groups and individuals affected by the devastating impact of opioid addiction.
The original settlement amount of $4.5 billion was widely criticized as insufficient to address the widespread harm caused by Purdue Pharma’s aggressive marketing of OxyContin and other opioids. The increased contribution will help provide much-needed funding for addiction treatment, prevention programs, and other initiatives aimed at combating the opioid crisis.
While the settlement is a positive step towards holding Purdue Pharma and the Sackler families accountable for their role in fueling the epidemic, many advocates argue that more needs to be done to address the root causes of addiction and ensure that those affected receive the support they need to recover.
As the legal proceedings continue, it is crucial that all parties involved remain committed to transparency, accountability, and justice for those impacted by the opioid crisis. The increased contribution from Purdue Pharma and the Sackler families is a step in the right direction, but there is still much work to be done to address the ongoing challenges posed by opioid addiction.
View on eBay
Looking to diminish those pesky pigmentation spots and achieve a more even skin tone? Look no further than Isis Pharma Neotone Serum! This powerful serum contains Niacinamide, a form of Vitamin B3 known for its skin brightening properties.
With regular use, this 30ML serum can help to lighten dark spots, reduce hyperpigmentation, and even out skin tone. Say goodbye to dull, uneven skin and hello to a brighter, more radiant complexion!
Give Isis Pharma Neotone Serum a try and see the amazing results for yourself. Your skin will thank you!
#Isis #Pharma #Neotone #Serum #Pigmentation #Spots #Skin #whitening #Niacinamid #30ML,niacinamide
View on eBay
Are you struggling with pigmentation spots on your skin and looking for an effective solution? Look no further than ISIS Pharma Neotone Serum! This powerful serum is specially formulated to target and lighten pigmentation spots, leaving your skin visibly brighter and more even-toned.
Each pack contains 30ml of serum, giving you a total of 60ml to help combat stubborn pigmentation spots. With regular use, you can expect to see a noticeable improvement in the appearance of your skin.
Don’t let pigmentation spots hold you back from having glowing, radiant skin. Try ISIS Pharma Neotone Serum today and say goodbye to uneven skin tone!
#ISIS #Pharma #Neotone #Serum #Pigmentation #Spots #Skin #whitening #30ML #Pack,niacinamide
DMSO 70/30 3 oz. Roll-on w/Aloe Vera 2 Pack 99.995% Low odor Pharma Grade
Price : 24.99
Ends on : N/A
View on eBay
Are you looking for a convenient and effective way to apply DMSO for pain relief and inflammation? Look no further than our DMSO 70/30 3 oz. Roll-on w/Aloe Vera 2 Pack!
This 99.995% low odor Pharma Grade DMSO roll-on is perfect for targeted application to areas of discomfort. The added Aloe Vera helps soothe the skin and promote healing.
Whether you’re dealing with arthritis, muscle soreness, or other aches and pains, this DMSO roll-on is a must-have in your pain relief arsenal. Don’t suffer any longer – try our DMSO 70/30 3 oz. Roll-on w/Aloe Vera 2 Pack today!
Price: $48.95 (as of Dec 29,2024 09:16:51 UTC – Details)
From the brand
Psycho Pharma
Potent High End Ingredients that Work!
Best Sellers
Top Performance
Package Dimensions : 4.37 x 3.58 x 3.54 inches; 12.52 ounces Item model number : EOI Date First Available : July 14, 2020 Manufacturer : Psycho Pharma ASIN : B08CTKDVTT Country of Origin : USA
#1 Strongest PreWorkout Powder NOT FOR BEGINNERS contains 8G Citrulline Pumps , 3.2G Beta alanine 350mg caffeine + 5mg yohimbine ,4mg Alpha yohimbe Potent 5 stim blend for fast-acting, long-lasting, hair raising energy, focus and power for the most intense workouts. EDGE OF INSANITY uses a high-grade, top-shelf stimulant and pump matrix balanced with GABA, a naturally occurring amino acid neurotransmitter, to achieve prolonged energy, “zen-like” focus, and the endurance and pumps that will make you never want to stop training… driving you to new personal records every time you use it! Razor’s Edge Focus: 350mg caffeine, ignited with a powerful blend of Theobromine, 5mg Yohimbe Bark, and 4mg Rauwoulscine (Alpha Y) gets you up and moving like an unstoppable freight train ready to crush PRs and achieve maximum gains. Perfect Powders Formula for Excellent Mixability. 8 Delicous Flavors
Customers say
Customers find the product effective and providing them with long-lasting energy. They enjoy the tasty flavors and consider it a quality pre-workout supplement. Many customers report that it helps increase strength, focus, and workout duration. However, opinions differ on whether the tingling sensation is noticeable or not.
AI-generated from the text of customer reviews
Are you ready to take your workouts to the next level? Look no further than Psycho Pharma’s Strongest High Stim Preworkout Powder – Edge of Insanity. This intense pre-workout supplement is designed to give you the pumps, strength, energy, and focus you need to crush your workouts like never before.
Edge of Insanity is not your average pre-workout. It is specifically formulated to provide you with the most intense and powerful ingredients to help you push your limits and achieve your fitness goals. With ingredients like Beta-Alanine, L-Citrulline, and caffeine, this pre-workout will give you the energy and focus you need to power through even the toughest workouts.
This pre-workout is perfect for those who are looking to take their training to the next level and want a supplement that can rival some of the most famous pre-workouts of the past. With Edge of Insanity, you can expect intense energy, insane pumps, and a feel-good focus that will have you crushing your workouts like never before.
So if you’re ready to experience the most intense pre-workout of your life, look no further than Psycho Pharma’s Edge of Insanity. Get ready to push your limits and achieve your fitness goals like never before.
#Psycho #Pharma #Strongest #High #Stim #Preworkout #Powder #Edge #Insanity #Intense #Pre #Workout #Supplement #Pumps #Strength #Energy #Feel #Good #Focus #Rivals #Famous #PWOs,BUCKED UP
Price: $4.99 (as of Dec 04,2024 23:19:32 UTC – Details)
AI Pharma: Artificial Intelligence in Drug Discovery and Development (Code and Compassion)
Artificial intelligence (AI) has revolutionized many industries, and the pharmaceutical sector is no exception. The use of AI in drug discovery and development has the potential to significantly accelerate the process of bringing new drugs to market, ultimately saving lives and improving patient outcomes.
AI algorithms can analyze vast amounts of data in a fraction of the time it would take a human researcher, identifying potential drug candidates and predicting their efficacy and safety profiles. This not only speeds up the drug discovery process but also reduces the cost and risk associated with developing new treatments.
But AI in pharma is not just about crunching numbers and generating insights. It also has the potential to bring a new level of compassion to the industry. By leveraging AI-powered tools, researchers can better understand the needs and preferences of patients, leading to more personalized and effective treatments.
For example, AI can analyze patient data to identify subpopulations that may benefit from a particular drug, or to predict how a patient is likely to respond to a certain treatment. This level of personalized medicine can lead to better outcomes and improved quality of life for patients.
However, it’s important to remember that AI is a tool, not a replacement for human expertise and compassion. While AI can analyze data and identify patterns, it takes human researchers to interpret the results and make decisions about how to move forward.
In the end, the combination of AI’s code and human compassion has the potential to revolutionize drug discovery and development, ultimately leading to better treatments for patients around the world. It’s an exciting time to be in the pharmaceutical industry, and AI is helping to pave the way for a brighter future.
#Pharma #Artificial #Intelligence #Drug #Discovery #Development #Code #Compassion
You must be logged in to post a comment.